Logo-npj
Submitted: 27 Feb 2018
Accepted: 04 Jun 2018
First published online: 19 Jun 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Nephropharmacol. 2018;7(2):104-109.
doi: 10.15171/npj.2018.22
  Abstract View: 583
  PDF Download: 340

Original

Gabapentin for treatment of restless legs syndrome among hemodialysis patients; a pilot study

Seyed Majid Mousavi Movahed 1, Gholamreza Alizadeh Attar 2, Fatemeh Hayati 2, Shahla Ahmadi Halili 2, Leila Sabetnia 2, Seyed Seifollah Beladi Mousavi 2 *

1 Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Ira
*Corresponding author: Seyed Seifollah Beladi Mousavi, Email: Email: Beladimusavi@yahoo.com

Abstract

Introduction: Unfortunately the restless leg syndrome (RLS) is a neglected issue among hemodialysis (HD) centers.

Objectives: The aim of our study was to find the efficacy of gabapentin at a low dose of 100 mg three times a week among HD patients with RLS. Patients and Methods: Around 21 patients with fulfilled the criteria of RLS were randomized to receive either gabapentin (100 mg) or placebo after HD session for 4 weeks. After 2 weeks of washout period, the patients were switched from gabapentin to placebo or placebo to gabapentin for another 4 weeks. Severity of RLS symptoms before and after management with medication or placebo was evaluated with standardized questionnaire.

Results: Twenty-one patients (10 females and 11 males with mean age of 58 years) were enrolled to the study. Before the study, all patients had questionnaire scores of 16 or greater and the mean score was 24.19± 7.96. After gabapentin administration (before or after crossover), the mean score significantly decreased from 24.19± 7.96 to 19.24± 9.87 (P=0.04). The mean score before and after placebo administration (before or after crossover) were 24.19± 7.96 and 18.89± 11.15 with no significant difference (P=0.09).

Conclusion: According to the results of the study gabapentin at a dose of 100 mg at the end of HD is a safe effective therapy for RLS. It can significantly reduce the intensity of RLS among these patients.

Keywords: End-stage renal disease, Gabapentin, Restless legs syndrome, Hemodialysis

Implication for health policy/practice/research/medical education:

In a study on 21 hemodialysis patients (10 females and 11 males with mean age of 58 years), we found that gabapentin at a dose of 100 mg is a safe effective therapy for restless legs syndrome. It can significantly reduce the intensity of restless legs syndrome among hemodialysis patients.

Please cite this paper as: Mousavi Movahed SM, Alizadeh Attar G, Hayati F, Ahmadi Halili S, Sabetnia L, Beladi Mousavi SS. Gabapentin for treatment of restless legs syndrome among hemodialysis patients; a pilot study. J Nephropharmacol. 2018;7(2):104-109. 

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 583

Your browser does not support the canvas element.


PDF Downloaded: 340

Your browser does not support the canvas element.